Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001193125-24-078293
Filing Date
2024-03-27
Accepted
2024-03-27 08:37:12
Documents
10

Document Format Files

Seq Description Document Type Size
1 424B3 d741878d424b3.htm 424B3 368823
2 GRAPHIC g741878g0313034236172.jpg GRAPHIC 1684
3 GRAPHIC g741878g0313034236482.jpg GRAPHIC 2544
4 GRAPHIC g741878g0313034236627.jpg GRAPHIC 2130
5 GRAPHIC g741878g0313034236789.jpg GRAPHIC 2243
6 GRAPHIC g741878g0313034236945.jpg GRAPHIC 2760
7 GRAPHIC g741878g0313034237270.jpg GRAPHIC 2171
8 GRAPHIC g741878g0313034237423.jpg GRAPHIC 2146
9 GRAPHIC g799876g0326054808442.jpg GRAPHIC 3946
10 GRAPHIC g799876g0326093257686.jpg GRAPHIC 3720
  Complete submission text file 0001193125-24-078293.txt   403629
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000 01161298780088
KAZIA THERAPEUTICS LTD (Filer) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 424B3 | Act: 33 | File No.: 333-276774 | Film No.: 24785935
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)